Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scan could Fine-Tune treatment timing for wet AMD

NCT ID NCT02868086

Knowledge-focused Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two ways of monitoring wet age-related macular degeneration (AMD) using eye scans: standard OCT B-scans and a newer technique called OCT angiography. The goal was to see if the newer scan could better detect when the disease is active, helping doctors decide when to give anti-VEGF injections. Sixty-eight adults with wet AMD were followed to compare how each scan affected treatment timing and vision stability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If OCT angiography proves better at detecting when wet AMD is active, it could help doctors time anti-VEGF injections more precisely, potentially preserving vision with fewer visits.
What could go wrong
This is a small, completed study (68 people) comparing imaging techniques, not testing a new treatment. The results may not change current practice or improve vision outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Oct 2016

Finished

Apr 2021

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient ≥ 50 years old * with exudative ARMD, * treated with intra-vitreous anti-angiogenics following a PRN protocol (pro re nata) * Absence of atrophy of the central pigment epithelium Exclusion Criteria * Opposition to participate in this research * Persons enjoying legal protection measure * Lack of affiliation to social security and universal health coverage * Pregnant or lactating * Another cause of Choroidal neovascularization * Unbalanced glaucoma * Eye surgery less than 3 months on the studied eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration

Contacts and locations

Locations

  • Fondation Ophtalmologique A. de Rotchschild

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.